ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 127 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $14,608,000 | +80.8% | 248,942 | +44.2% | 0.11% | +71.0% |
Q3 2017 | $8,078,000 | +193.1% | 172,602 | +125.3% | 0.06% | +158.3% |
Q2 2017 | $2,756,000 | +13.0% | 76,602 | -3.3% | 0.02% | +9.1% |
Q1 2017 | $2,439,000 | -33.1% | 79,200 | -27.2% | 0.02% | -33.3% |
Q4 2016 | $3,645,000 | -8.6% | 108,800 | -27.4% | 0.03% | -13.2% |
Q3 2016 | $3,989,000 | +1252.2% | 149,900 | +1018.7% | 0.04% | +1166.7% |
Q2 2016 | $295,000 | -88.6% | 13,400 | -84.8% | 0.00% | -88.9% |
Q1 2016 | $2,589,000 | +120.5% | 88,144 | +171.4% | 0.03% | +92.9% |
Q3 2015 | $1,174,000 | -88.9% | 32,481 | -86.2% | 0.01% | -88.5% |
Q2 2015 | $10,599,000 | +5121.2% | 235,581 | +5789.5% | 0.12% | +3966.7% |
Q4 2014 | $203,000 | -95.4% | 4,000 | -96.4% | 0.00% | -95.4% |
Q3 2014 | $4,400,000 | +801.6% | 111,200 | +811.5% | 0.06% | +712.5% |
Q1 2014 | $488,000 | -55.1% | 12,200 | -69.3% | 0.01% | -55.6% |
Q4 2013 | $1,086,000 | – | 39,800 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |